Monday, 10 Dec 2018

You are here

Diet During Pregnancy May Influence Future Allergic or Autoimmune Disease

A systematic review of the literature on the relationship between diet during pregnancy, lactation, or the first year of life suggests that maternal ingestion of probiotic and fish oil supplementation may reduce risk of eczema and allergic sensitization to food, respectively.

Using the GRADE process, the authors found that 19 intervention trials suggest that oral supplementation with probiotics during late pregnancy and lactation may reduce risk of eczema (Risk Ratio [RR] 0.78; 95% CI 0.68–0.90).

The also found 6 trials suggesting that fish oil supplementation during pregnancy and lactation may reduce risk of allergic sensitisation to egg (RR 0.69).

Weaker evidence exists supporting that breastfeeding reduces risk of eczema during infancy, reduces the risk of type 1 diabetes mellitus or that probiotics reduce risk of allergic sensitisation to cow’s milk.

They found no evidence that prebiotic supplements, maternal allergenic food avoidance, and vitamin, mineral, fruit, or vegetable intake may influence risk of allergic or autoimmune disease.

 

 

Add new comment

More Like This

SLE and Risk of Malignancy

The risk for cancer in systemic lupus erythematosus (SLE) patients has been inconsistently studied.  A new metanalysis shows that SLE has an increased risk for 16 specific cancers and decreased risk for prostate cancer and cutaneous melanoma. 

The Benefits of a Lupus Clinic

A comparative cohort study assessing the quality of care in patients with systemic lupus erythematosus (SLE) suggests that a dedicated lupus clinic has better quality measure performance compared to lupus management in a general rheumatology clinic.

A study from Rush University enrolled 150 consecutive SLE patients - with 73 followed in the general rheumatology clinic and 77 followed in a dedicated lupus clinic. 

Diagnosing Early Lupus from Mimics

A multicenter study of early systemic lupus erythematosus (SLE) patients examined manifestations at disease onset and found that certain clinical features can help to distinguish early SLE from other SLE‐mimicking conditions. 

High CV Risk in Lupus

Patients with systemic lupus erythematosus (SLE) remain at risk for accelerated atherosclerosis, and important questions have yet to be answered, British investigators reported.

AURA-LV Trial - Voclosporin Effective in Lupus Nephritis

The AURA-LV trial assessed voclosporin, a calcineurin inhibitor in patients with active lupus nephritis (LN) and found that low-dose voclosporin may be successfully added to mycophenolate mofetil and corticosteroids to controll active LN.